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WS5.1 A high degree of variation in virulence of clonal Burkholderia
cenocepacia ST32 isolates from cystic ﬁbrosis patients in
zebra ﬁsh embryos
K. Dedeckova1, A. Vergunst2, P. Drˇevı´nek1. 1Charles University, Department of
Medical Microbiology, Prague, Czech Republic; 2INSERM U1047, Universite´ de
Montpellier 1, UFR Me´decine, Nimes, France
Strain Burkholderia cenocepacia sequence type (ST) 32 caused infections in ca.
30% of the Czech cystic ﬁbrosis (CF) patients and in some cases ended up with
a fatal cepacia syndrome. To evaluate ST32 virulence and differences in virulence
among individual isolates, we tested 31 B. cenocepacia ST32 isolates obtained at
different phases of chronic infection from 14 patients (28 isolates from sputum, 3
from blood cultures) in a zebra ﬁsh embryo infection model.
Results from survival assay in zebra ﬁsh embryos split the isolates into following
virulence groups: group A contained 14 isolates, which were able to kill 100% of
infected embryos within 64−96 hours post infection (hpi). Group B was composed
of 13 isolates with intermediate virulence that killed 40−75% of embryos by
120 hpi. Four isolates (group C) were able to kill 0−20% of all embryos by 120 hpi.
Blood isolate 1 (group B) and 2 (group C) were analyzed in more detailed. Real time
analysis revealed that isolate 1 was able to cause systemic infection and only 30% of
embryos were alive at 120 hpi. Isolate 2 did not cause systemic infection, embryos
could control infection and they were alive at 120 hpi. To perform kinetics assay, ﬁve
embryos were collected at 4, 24 and 48 hpi and treated for bacterial enumeration.
Isolates differed each other in growth kinetics at 24 and 48 hpi as follows: for
isolate 1, 3.70±0.24 and 4.17±0.13 log CFU and for isolate 2, 0.25±0.16 and
0.83±0.13 log CFU, respectively.
Our results indicate variation in virulence potential between B. cenocepacia ST32
isolates originating not only from different patients, but also from one patient.
Supported by GAUK307311; IGA MZ NT12405−5; MS MT LD11029.
WS5.2 Toll-like receptor 9 deﬁciency protects mice against
Pseudomonas aeruginosa pulmonary infection
F. Ben Mohamed1,2, M. Medina1,2, Y. Zhang1,2, S. Maschalidi3, M. Chignard1,2,
B. Manoury3, L. Touqui1,2. 1Institut Pasteur, Unite´ de De´fense Inne´e et
Inﬂammation, Paris, France; 2INSERM U874, Paris, France; 3INSERM, U.1013,
Paris, France
Pseudomonas aeruginosa is an opportunistic pathogen involved in nosocomial
infections. While a number of studies have demonstrated the roles of TLR2, TLR4
and TLR5 in host defense to P. aeruginosa infection, the implication of TLR9 in this
process has been overlooked. Here, we showed that P. aeruginosa DNA stimulated
TLR9 in both alveolar macrophages (AMs) and airway epithelial cells (AECs).
This activation required asparagine endopeptidase- and endosomal acidiﬁcation.
Interestinglly, TLR9−/− mice resisted to lung infection by P. aeruginosa as compared
to WT mice. The resistance of TLR9−/− mice to P. aeruginosa infection was
associated with:
i. a higher ability of TLR9−/− AMs to kill P. aeruginosa
ii. a rapid increase in the production of pro-inﬂammatory cytokines TNFa, IL-1b
and IL-6 and
iii. an increase in nitric oxyde (NO) production and inductible NO synthase (iNOS)
expression in both lungs and AMs.
Interestingly, inhibition of both IL-1b and NO production resulted in a signiﬁcant
decrease of P. aeruginosa clearance by AMs. Altogether these results indicate that
both IL-1b and NO play a key role in AM-mediated clearance of P. aeruginosa.
TLR9 plays a detrimental role in pulmonary host defense toward this pathogen by
dowregulation IL-1b and NO production by AMs.
WS5.3 GSNOR inhibitors as potential, novel anti-inﬂammatory
therapy in cystic ﬁbrosis
S. Shoemaker1, J. Troha1, S. Gabriel1, C. Scoggin1, J. Blonder1, S. Mutka1,
S. Donaldson2. 1N30 Pharmaceuticals, Inc., Boulder, CO, USA; 2University of
North Carolina, Chapel Hill, NC, USA
Small molecule inhibitors of the enzyme, S-nitrosoglutathione reductase (GSNOR)
discovered and developed by N30 Pharmaceuticals, Inc., (N30 Pharma) may provide
a novel therapeutic strategy in cystic ﬁbrosis (CF). These inhibitors preserve
endogenous levels of S-nitrosoglutathione (GSNO), an important signaling molecule
that exerts its effects through modulation of protein function. GSNO levels have
been found to be lower than normal in the CF lung, possibly through increased
GSNOR activity. N30 Pharma’s GSNOR inhibitors have demonstrated improved
chloride channel function in in vitro and in vivo models of CF as well as
potent anti-inﬂammatory effects in experimental models of chronic obstructive
pulmonary disease (COPD). The inﬂammatory pathways through which GSNOR
inhibitors exert their effects have relevance to the pathogenesis of CF. In an
elastase-induced model of emphysema, GSNOR inhibition resulted in signiﬁcant
effects on preserving lung architecture and decreasing airway hyper-responsiveness
compared to vehicle controls. In an 11-day tobacco smoke-induced model of COPD,
GSNOR inhibition signiﬁcantly reduced bronchoalveolar lavage neutrophils and
decreased airway hyper-responsiveness. The anti-inﬂammatory effects of GSNOR
inhibitors have been shown to be mediated in part via down regulation of NFúB
through S-nitrosation of the p65 subunit. Other effects include direct antioxidant
effects of GSNO and inhibition of a variety of chemokines and cytokines. The ﬁrst
of N30 Pharma’s novel inhibitors is currently being studied in patients homozygous
for F508del-CFTR. This study includes a comprehensive evaluation of biomarkers
of inﬂammation and CFTR function.
WS5.4 Increased production of IL-17A in circulating Th17 and
dysfunctional Tregs in adults with cystic ﬁbrosis-related
diabetes
S. Ziai1,2, R. Rabasa-Lhoret1,2,3, M.-S. Gauthier1, M. Mailhot3, L. Coderre1,
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Cystic ﬁbrosis-related diabetes (CFRD), a frequent complication of CF, is associated
with decreased lung function and increased mortality. Our preliminary data showed
that CF patients, regardless of their glucose tolerance, have increased glucose
ﬂuctuations (GF) and hyperglycemia (HG) when compared to healthy controls
(HC) that could be associated with altered immune reactivity. IL-17A, produced by
Th17 and dysfunctional regulatory T-cells (Treg), is a pro-inﬂammatory cytokine
associated with diabetes and CF lung disease. Its role in CFRD is unknown.
Objectives: Determine if Th17 and Treg cells of CF patients, particularly CFRD
patients, produce increased levels of IL-17A.
Methods: Peripheral blood was drawn from HC (n = 7), non-diabetic (n = 6) and pre-
diabetic (n = 2) CF and CFRD patients (n = 7). Lymphocytes were isolated, incubated
(24 h, 5mM glucose), stimulated or not with phorbol myristate acetate (PMA) and
phytohemagglutinin (PHA) and then stained for cell surface markers (CD3, CD4,
CD25), FoxP3 and IL-17A. The proportion of Th17 (CD3+CD4+CD25lowFoxP3−)
and Treg (CD3+CD4+CD25highFoxP3+) cells producing IL-17A and their relative
production were determined by ﬂow cytometry.
Conclusions: Stimulation with PMA and PHA increased the proportion of Th17
and Treg cells producing IL-17A and the quantity they produce (p< 0.02). The
proportion of Th17 and Treg cells producing IL-17A of CF patients and HC were
similar (p> 0.05). However, Th17 cells of CFRD patients (p = 0.01) and Treg cells
of all CF patients (p = 0.004) produced increased levels of IL-17A as compared to
those of HC. Thus, increased production of IL-17A by circulating Th17 and Treg
cells is associated with CFRD.
